Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases. A prominent side effect of TMZ is induction of profound lymphopenia, which some suggest may be incompatible with immunotherapy. Conversely,...

Full description

Bibliographic Details
Main Authors: Luis A Sanchez-Perez, Bryan D Choi, Gary E Archer, Xiuyu Cui, Catherine Flores, Laura A Johnson, Robert J Schmittling, David Snyder, James E Herndon, Darell D Bigner, Duane A Mitchell, John H Sampson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3601076?pdf=render

Internet

http://europepmc.org/articles/PMC3601076?pdf=render

Similar Items